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Abstract
Aim Approximately 20%–30% of patients with ulcerative
colitis (UC) will undergo surgery during their disease
course, the vast majority being elective due to chronic
refractory disease. The risks of elective surgery are reported
variably. The aim of this systematic review and meta-analysis
is to summarize the outcomes after elective surgery for UC.
Methods A systematic review was conducted that analysed
studies reporting outcomes for elective surgery in the mod-
ern era (>2002). It was prospectively registered on the
PROSPERO database (ref: CRD42018115513). Searches
were performed of Embase and MEDLINE on 15 January
2019. Outcomes were split by operation performed. Pri-
mary outcome was quality of life; secondary outcomes were
early, late and functional outcomes after surgery. Outcomes
reported in five or more studies underwent a meta-analysis
of incidence using random effects. Heterogeneity is
reported with I2, and publication bias was assessed using
Doi plots and the Luis Furuya-Kanamori index.
Results A total of 34 studies were included (11 774
patients). Quality of life was reported in 12 studies,
with variable and contrasting results. Thirteen outcomes
(eight early surgical complications, five functional out-
comes) were included in the formal meta-analysis, all of
which were outcomes for ileal pouch–anal anastomosis
(IPAA). A further 71 outcomes were reported (50
IPAA, 21 end ileostomy). Only 14 of 84 outcomes
received formal definitions, with high inter-study varia-
tion of definitions.
Conclusion Outcomes after elective surgery for UC are
variably defined. This systematic review and meta-analy-
sis highlights the range of reported incidences and pro-
vides practical information that facilitates shared
decision making in clinical practice.
Keywords ulcerative colitis, surgery, inflammatory
bowel disease, outcomes research
Introduction
Ulcerative colitis (UC) is a chronic, relapsing–remitting
condition of the colon and rectum [1]. It causes debili-
tating symptoms such as bleeding per rectum, frequency
of defaecation, abdominal pain and tenesmus [2]. UC is
managed primarily via a variety of anti-inflammatory
and immunosuppressant medications such as aminosali-
cylates, corticosteroids, anti-tumour necrosis factor
(anti-TNF) agents, vedolizumab, ustekinumab and
tofacitinib [3–7]. Despite medical treatment, approxi-
mately 20%–30% of patients require surgery during their
disease course [8]. Patients may undergo emergency
surgery; however, the vast majority of patients undergo
elective surgery due to chronic refractory disease [9].
The decision between elective surgery and continued
medical therapy is said to be preference-sensitive, in that
it depends on patient preferences due to clinical equi-
poise in the area [10]. The same can be said for the
decision between reconstructive operations and remain-
ing with a permanent stoma. The most common recon-
structive operation – ileal pouch–anal anastomosis
(IPAA) – avoids a permanent stoma; however, it is asso-
ciated with complications such as pouchitis, increased
stool frequency and faecal incontinence [11]. A perma-
nent stoma offers more control over excretory functions
but carries significant psychosocial consequences and
complications such as parastomal hernia [12].
Shared decision making is a process whereby clini-
cians share the most up-to-date clinical information on
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the risks and benefits of a procedure to allow the
patient to make a decision based on their preferences
[13]. Operative options for UC, particularly reconstruc-
tive operations, remain low volume operations and
complications from such operations are reported vari-
ably within the literature [11,14]. One previous system-
atic review reports outcomes after colectomy, but
includes both emergency and elective procedures in data
synthesis [11]. In order to fully counsel our patients, it
is imperative to have accurate and up-to-date informa-
tion on the safety and outcomes of elective surgery for
UC.
The aim of this review is to summarize evidence of
the most up-to-date clinical outcomes following elective
surgery for UC, including both short- and long-term
complications, functional outcomes and quality of life
(QoL). This review forms part of a larger body of work
in the creation of a decision aid for patients considering
elective surgery or ongoing medical therapy.
Method
Methodological framework
The review was conducted with reference to the
Cochrane Handbook for Systematic Reviews [15] and is
reported in line with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines [16]. The review protocol was prospectively
registered on the PROSPERO database (ref:
CRD42018115513) [17]. An electronic database search
was undertaken on 15 January 2019 using a pre-defined
search strategy (Table S1). The search strategy was kept
deliberately broad to encompass as many studies as pos-
sible. The electronic databases searched were MED-
LINE (via OvidSP) and Embase (via OvidSP). Titles
and abstracts were screened for eligibility using the Ray-
yan web application [18] by two independent research-
ers (DMB, AMF), with conflicts resolved by a third
researcher (MJL). Full texts were retrieved and screened
against the eligibility criteria. All systematic reviews
returned from the search were hand searched for papers
which were reassessed at full text against the inclusion
criteria.
Eligibility criteria
All studies in English including adult patients
(> 18 years of age) reporting any outcome after elec-
tive surgery for UC performed during or after 2002
(post-biologic introduction) were eligible for inclu-
sion. This approach has been adopted previously in
the literature [11] as it ensures up-to-date surgical
outcomes are collected, primarily as biologic use
reduced the need for surgical intervention but also
due to universal biologic use affecting postoperative
outcomes. Additionally, surgical practice has altered
and it is imperative that outcomes are synthesized
which reflect modern surgical practice. For studies
performed over a number of years prior to and
including 2002, the range was set at 5 years before
2002, i.e. 1997–2005. Surgical procedures included
the following: total and subtotal colectomy with per-
manent end ileostomy or diverting ileostomy, IPAA
and ileorectal anastomosis, with any performed as
open, laparoscopic or robotic approaches, in one, two
or three stages. Only studies of 20 patients or more,
with a diagnosis of UC, were included. This was cho-
sen as the threshold to capture low sample size QoL
studies but exclude case series, case reports or studies
with a very small sample which may bias pooling of
results. Studies with a mixed population, e.g. UC and
familial adenomatous polyposis, were only included if
data for patients with UC could be separately identi-
fied. Case reports, conference abstracts or review arti-
cles were excluded.
Outcomes
The primary outcome was QoL, as previous work by
this group illustrated this as the preferred patient infor-
mational preference preoperatively [19]. Secondary out-
comes were early and late surgical complications as
defined by the individual study (a method used previ-
ously in systematic reviews for UC [11]) as well as func-
tional outcomes after surgery.
Data extraction
Data were extracted by one investigator (AMF) and
verified by a second (DMB). All data were entered
into Microsoft Excel (Microsoft, Redmond, Wash-
ington, USA). Basic descriptive details for papers col-
lected were first author, year of publication, journal
of publication, country of origin, study period, sample
size, surgical procedure(s) and study design. Data
were also collected on any outcome (see above)
reported within the paper, and the relevant incidence
rate was recorded.
Statistical analysis
QoL data are predominantly reported narratively due to
the wide range of methods used to report QoL data.
Where possible, figurative data are used. Postoperative
outcomes were split and pooled according to the
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different operation(s) reported in each study. Outcomes
that are reported in less than five studies are reported as
ranges to allow quantification of the uncertainty around
each event. For outcomes that were reported in five or
more studies, a meta-analysis of the incidence of each
outcome was undertaken using the double arcsine
method, with the random-effects (DerSimonian–Laird)
model. There is no recommended number of studies
required for use of meta-analysis methods [20]; how-
ever, we opted for five studies to factor in studies of
small sample size to allow more accurate pooling of
results. The I2 statistic was used as a measure of hetero-
geneity which was not due to chance alone. Hetero-
geneity was classified as low (< 25%), moderate (25%–
75%) or high (> 75%). Publication bias was assessed
using the Luis Furuya-Kanamori (LFK) index and by
visually inspecting Doi plots. Doi plots and the LFK
index were chosen as they have been shown to have a
higher sensitivity when used on meta-analyses of this
size [21]. An LFK index of 1 to 1 indicates no asym-
metry in the plot, 1–2 or (2 to 1) suggests minor
asymmetry and > 2 (or < 2) indicates major asymme-
try. Statistical analysis was undertaken using the MetaXL
(www.epigear.com) plug-in for Microsoft Excel. A sen-
sitivity analysis was planned to include studies with a
sample size of 100 or greater. Post hoc analysis of patient
demographic data was performed to identify the possi-
bility of subgroup analyses.
Risk of bias
Risk of bias was assessed by one researcher (DMB) and
verified by a second (MJL). Risk of bias was assessed
using the validated Joanna Briggs Institute prevalence
critical appraisal tool [22]. This assessment tool is a vali-
dated tool for use in systematic reviews of incidence
and prevalence. It contains 10 objective questions
(Table S6) to assess the quality of papers reporting inci-
dence and prevalence. Quality of papers was only
assessed at full text.
Deviation from the protocol
Appendicectomy was originally listed as included. How-
ever, after discussion it was excluded due to it not cur-
rently being routinely offered as a surgical option for
UC patients in the UK. We also aimed to assess risk of
bias using the ROBINS tool; this was found to be an
inappropriate tool for assessing risk of bias in our study,
however, and thus we changed to the prevalence tool
mentioned above. The Cochrane Library was not
searched for pragmatic reasons.
Results
Study selection
The study selection process is summarized in Fig. 1.
The initial search strategy identified 5420 papers, of
which 3777 remained following removal of duplicates.
Following screening of abstracts, 277 articles were
assessed at full text, of which 245 were excluded, leav-
ing a total of 32 papers for inclusion in analysis. Eight
systematic reviews were identified in the initial search
which contained 156 papers. Twenty-two were assessed
at full text, two of which met the inclusion criteria. This
left a total of 34 papers to be included within the final
analysis.
Study characteristics
Study characteristics of the 34 included studies are
shown in Table 1. The demographics of patients
included in each study are shown in Table 2.
In total, 11 774 patients with UC were enrolled
across the 34 studies. Of these, 11 686 underwent
elective surgery for UC and 88 remained on contin-
ued medical therapy. The patients on continued medi-
cal therapy were included because they were reported
in two studies which were relevant to the outcomes
of this review as they compared QoL of elective sur-
gery with continued medical therapy [42,53] A variety
of surgical procedures were performed by a laparo-
scopic, open or robotic approach in one, two or three
stages, and included IPAA and subtotal colectomy
with permanent end ileostomy. None of the 34 stud-
ies were randomized clinical trials. Of the 34 studies
included, the most common country of origin was
the USA (n = 15), whilst the remaining studies
were conducted in 13 different countries including
Japan (n = 4), the Netherlands (n = 3) and China
(n = 2).
Quality of life
Twelve studies assessed QoL in a variety of different
patient populations, using a range of different methods
and questionnaires (Table S2). Six studies assessed
QoL in postoperative IPAA cohorts alone [23,25,26,
30,33,48], two compared QoL before and after surgery
for IPAA [28,54], two compared postoperative cohorts
of IPAA to ileostomy [29,39] and two compared IPAA
to continued medical therapy [42,53]. Due to the large
variability in QoL questionnaires used, the variation in
study populations and also inter-study variation of
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Records identified through
database searching
(n = 5,420)
Records identified through
other sources (n = 0)
Titles and abstracts screened
(n = 3,777)
Duplicates excluded
(n = 1,643)
Full text articles screened
(n = 277)
Records excluded (n = 3,500)
Full text articles included
(n = 32)
Full text articles excluded (n = 244):
Reasons;
>5 years before 2002 (n = 90)
Abstract (n = 48)
Mixed population (n = 44)
Not elective surgery outcomes (n = 25)
Non-English Language (n = 11)
Review Article (n = 11)
Systematic reviews (n = 8)
Editorial (n = 3)
Letter (n = 3)
<20 patients in study (n = 2)
Studies included in final
analysis (n = 34)
Hand search and full text
assessment of papers in
systematic reviews (n = 2)
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram summarising study selection process.
ª 2020 The Authors. Colorectal Disease published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland4
Outcomes after surgery for ulcerative colitis D. M. Baker et al.
analysis of questionnaires, a formal synthesis of results
was not possible. We narratively describe our results
below.
A total of six studies report QoL in postoperative
IPAA cohorts. Two studies reported general health to
be comparable to that of the general population
[23,33] following IPAA surgery, whilst physical and
mental health were reportedly lower than the general
population [23]. Additionally, one study [48] reported
QoL to be average or good in 97.4% of the cohort fol-
lowing IPAA surgery. Sexual desire and sexual satisfac-
tion were reported to increase post-surgery [26],
Table 1 Summary of included studies.
Study Country
Study time
period Design Sample size Intervention(s)
Aghdaei et al. [23] Iran NR Observational
cross-sectional survey
68 IPAA
Baek et al. [24] USA 1998–2004 Retrospective cohort 149 Open IPAA, L-IPAA
Barnes et al. [25] USA 2011–2016 Prospective cohort 243 IPAA
Berndtsson et al. [26] Sweden NR Prospective cohort 43 IPAA
Cohan et al. [27] USA 2005–2012 Retrospective cohort 2493 1-stage and 2-stage IPAA
Cohan et al. [28] USA 2006–2014 Prospective cohort 37 IPAA and end ileostomy
Exarchos et al. [29] Greece 2010–2016 Prospective cohort 47 RPC with IPAA
Fasen et al. [30] USA 1998–2008 Prospective cohort 73 2-stage and 3-stage IPAA
Fichera et al. [31] USA 2002–2007 Prospective cohort 179 Open IPAA, L-IPAA
Hasegawa et al. [32] Japan 2002–2006 Retrospective cohort 21 L-IPAA
Heikens et al. [33] Netherlands 1998–2005 Prospective cohort 71 IPAA
Hicks et al. [34] USA 2000–2011 Retrospective cohort 99 IPAA
Holubar et al. [35] USA 2000–2007 Prospective cohort 44 Laparoscopic total
proctocolectomy with end
ileostomy
Ide et al. [36] Japan 2001–2012 Retrospective cohort 234 RPC with IPAA
Ikeuchi et al. [37] Japan 1999–2003 Prospective cohort 242 1-stage and 2-stage IPAA
Kawamura et al. [38] Japan 2002–2010 Retrospective cohort 28 Laparoscopic RPC with IPAA
Kuruvilla et al. [39] USA 2011 Cross-sectional survey 59 IPAA, subtotal colectomy with
end ileostomy
Mark-Christensen et al. [40] Denmark 2003–2014 Prospective cohort 251 Robotic-assisted IPAA,
open IPAA
McKenna et al. [41] USA 2002–2013 Retrospective cohort 909 Open, laparoscopic, 2-stage
and 3-stage IPAA
Meijs et al. [42] Netherlands 2013 Prospective cohort 58 IPAA
Mineccia et al. [43] Italy 2005–2015 Retrospective cohort 78 L-IPAA, open IPAA
Moore et al. [44] USA 2002–2008 Case–control 60 IPAA
Pandey et al. [45] USA 2002–2008 Prospective cohort 118 2-stage and 3-stage IPAA
Patel et al. [46] USA 2005–2010 Retrospective cohort 4664 Elective colectomy
Ryoo [47] South Korea 1998–2013 Prospective cohort 72 IPAA
Salehimarzijarani et al. [48] Iran 2006–2012 Cross-sectional survey 39 RPC with IPAA
Samples et al. [49] USA 2003–2010 Retrospective cohort 248 2-stage IPAA
Tan et al. [50] Singapore 1999–2011 Retrospective cohort 89 IPAA
Telem et al. [51] USA 2002–2007 Retrospective cohort 90 Laparoscopic and open subtotal
colectomy with end ileostomy
Tulchinsky et al. [52] Israel NR Prospective cohort 44 RPC with IPAA
van Gennep et al. [53] Netherlands
and Belgium
2010–2015 Retrospective cohort 118 IPAA
Xu et al. [54] China 2008–2016 Retrospective cohort 58 IPAA
Zhu and Xing [55] China 2010–2013 Prospective cohort 40 L-IPAA and open IPAA
Zittan et al. [56] Canada 2002–2013 Retrospective cohort 758 2-stage and 3-stage IPAA
IPAA, ileal pouch–anal anastomosis; L-IPAA, laparoscopic ileal pouch–anal anastomosis; NR, not reported; RPC, restorative procto-
colectomy.
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Table 2 Summary of patient demographics of included studies.
Study Study subgroups
Age, years, mean (SD)
[range] Sex (% men)
Preoperative medication
use (%)
Aghdaei et al. [23] IPAA 39.3 (11.1) 56.9 NR
Baek et al. [24] Open IPAA
Lap IPAA
Open: 34.5 (10.3)
Lap: 33.3 (11.3)
Open: 40.7
Lap: 41.4
NR
Barnes et al. [25] No IPAA symptoms
IPAA symptoms
IPAA no symptoms: 18–
39 = 48%, 40–59 = 43%,
> 60 = 9%
IPAA symptoms: 19–
39 = 55%, 40–59 = 37%,
> 60 = 8%
IPAA no symptoms: 39
IPAA symptoms: 29
NR
Berndtsson et al.
[26]
IPAA 35 [22–53] 58.1 NR
Cohan et al. [27] Age < 50
Age 51–60
Age > 60
Age < 50: n = 1831
Age 51–60: n = 408
Age > 60: n = 254
Age < 50: 55.8
Age 51–60: 65.7
Age > 60: 63
NR
Cohan et al. [28] Male patient
Female patient
Male partner
Female partner
Male patient: 41 [26–76]
Female patient: 34 [25–76]
Male partner: 33 [26–69]
Female partner: 42 [26–
80]
Male patient: n = 25
Female patient: n = 12
Male partner: n = 12
Female partner: n = 25
NR
Exarchos et al. [29] RPC with IPAA < 50 = 70.2% 63.8 NR
Fasen et al. [30] IPAA 38.1 (11.2) 67 NR
Fichera et al. [31] Open IPAA
Lap IPAA
Open: 36.9
Lap: 36.3
Open: 57.8
Lap: 50.7
Steroids: 99
Anti-TNF: 25
Hasegawa et al. [32] IPAA 29 [16–64] 76.2 NR
Heikens et al. [33] IPAA 35.1 [29.3–40.3] 40.8 NR
Hicks et al. [34] IPAA 32.6 (1.4) 55.6 Steroids: 66.7
Anti-TNF: 26.3
Other: 43.4
Holubar et al. [35] HALS RPC + end
ileostomy
Lap RPC + end
ileostomy
Incision-less
RPC + end ileostomy
HALS: 63 [30–79]
Lap: 70 [50–83]
Incision-less: 69 [51–86]
HALS: 70
Lap: 38
Incision-less: 38
NR
Ide et al. [36] Pelvic sepsis IPAA
Non-pelvic sepsis
IPAA
Pelvic sepsis: 33.2 (15.2)
Non-pelvic sepsis: 26.1
(15.5)
Pelvic sepsis: 31
Non-pelvic sepsis: 54.1
NR
Ikeuchi et al. [37] 1-stage IPAA
2-stage IPAA
1 stage: 30 [15–69]
2 stage: 35.5 [16–68]
1 stage: 48
2 stage: 51
NR
Kawamura et al. [38] IPAA in severe UC
IPAA in mild-mod UC
Severe: 34 [16–64]
Mild-mod: 35 [16–66]
Severe: 57
Mild-mod: 62
Other severe: 57
Other mild-mod: 43
Kuruvilla et al. [39] IPAA
Permanent ileostomy
IPAA: 50.7 (14.5)
Ileostomy: 54.8 (15.6)
IPAA: 65.7
Ileostomy: 69.6
NR
Mark-Christensen
et al. [40]
Open IPAA
Robot assisted IPAA
Open: 36.5 (12.7)
Robot: 35.4 (13.6)
Open: 56
Robot: 52
NR
McKenna et al. [41] IPAA in obese patients
IPAA in non-obese
patient
Obese: 42.5
Non-obese: 37.1
Obese: 57.8
Non-obese: 59.7
Steroids obese: 44.2
Steroids non-obese: 37.2
Anti-TNF obese: 19
Anti-TNF non-obese: 21.3
Other obese: 21.4
Other non-obese: 21.9
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despite a different study reporting that there was no
change in the quality of relationships after surgery [30].
Barnes et al. [25] report 82% of the patients in their
cohort to experience pouch-related symptoms – with an
impact on QoL through pain interference, depression,
decreased social function and increased levels of fatigue.
Two studies reported QoL both before and after sur-
gery for IPAA to allow for a comparison of QoL
parameters. Cohan et al. [28] report a significant
increase in the median score for both men and women
in physical function (men 60–91/100, women 49–85/
100) and mental function (men 62–83/100, women
57–80/100) after IPAA surgery when using the Short
Form 36 (SF-36) questionnaire. They also report a sig-
nificant increase in sexual function in both sexes. Xu
et al. [54] describe 54% of the patients in their cohort
Table 2 (Continued).
Study Study subgroups
Age, years, mean (SD)
[range] Sex (% men)
Preoperative medication
use (%)
Meijs et al. [42] IPAA
Continued anti-TNF
IPAA: 42 [22–67]
Anti-TNF: 45 [19–68]
IPAA: 51.7
Anti-TNF: 35
NR
Mineccia et al. [43] Open IPAA
Lap IPAA
Open: 45
Lap: 37
Open: 72.9
Lap: 56.6
Steroids open: 97.9
Steroids lap: 100
Anti-TNF open: 4.2
Anti-TNF lap: 16.7
Other open: 47.9
Other lap: 86.6
Moore et al. [44] African American
IPAA patients
Caucasian patients
African American: 39.7
Caucasian: 45.8
African American: 41.7
Caucasian: 56.3
NR
Pandey et al. [45] 2-stage IPAA
3-stage IPAA
2 stage: 37.5 (12.5)
3 stage: 35 (10.9)
2 stage: 50
3 stage: 60
Steroids 2 stage: 67
Steroids 3 stage: 96
Anti-TNF 2 stage: 16
Anti-TNF 3 stage: 43
Patel et al. [46] Elective colectomy 43.95 56.7 Steroids: 39.9
Ryoo [47] IPAA < 40 = 34.7% 38.9 NR
Salehimarzijarani
et al. [48]
RPC with IPAA 37 [18–63] 51.3 NR
Samples et al. [49] Classic 2-stage
Variant 2-stage
Classic: 38 [28–54]
Variant: 38 [26–52]
Classic: 51.8
Variant: 54.1
Steroids classic: 73.4
Steroids variant: 83.5
Anti-TNF classic: 20.1
Anti-TNF variant: 32.1
Other classic: 44.6
Other variant: 31.2
Tan et al. [50] IPAA 46 [28–54] 61.8 NR
Telem et al. [51] Open IPAA
Lap IPAA
Open: 42.6 (4.48)
Lap: 39.8 (5.62)
Open: 61
Lap: 45
Steroids open: 95
Steroids lap: 90
Other open: 89
Other lap: 83
Tulchinsky et al.
[52]
RPC with IPAA
pregnancy outcomes
30 (8.0) 0 NR
van Gennep et al.
[53]
IPAA
Anti-TNF
IPAA: 45.8 (12.4)
Anti-TNF: 40.9 (14.8)
IPAA: 45.8
Anti-TNF: 57.6
NR
Xu et al. [54] IPAA 37.5 [27.8–52] 32.8 Steroids: 51.7
Other: 12.1
Zhu and Xing [55] Open IPAA
HALS IPAA
Open: 43[22–65]
HALS: 39 [23–74]
Open: 45
HALS: 40
NR
Zittan et al. [56] IPAA 37.1 (12.1) 57.6 Steroids: 50.9
Anti-TNF: 57.6
Other: 18.8
HALS, hand assisted laparoscopic surgery; IPAA, ileal pouch–anal anastomosis; NR, not reported; RPC, restorative proctocolec-
tomy; Anti-TNF, anti-tumour necrosis factor.
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having over a 50% improvement in their Cleveland Glo-
bal Quality of Life (CGQL) score following IPAA sur-
gery.
Two studies compared IPAA patients to ileostomy
patients. One of these studies used questionnaires on a
patient population before and 8 weeks after closure of
their defunctioning ileostomy [29]. This study reported
a significant increase in both the Inflammatory Bowel
Disease Questionnaire (153.3–178/250, P < 0.05) and
CGQL (17.4–23.4/30, P < 0.001) scores following
closure of the ileostomy. This is in keeping with the
study by Kuruvilla et al. [39] who also describe a signif-
icantly increased CGQL in IPAA patients compared to
ileostomy cohorts (0.9 vs 0.8 respectively, P < 0.05).
Contrary to this, Kuruvilla et al. also utilize the Inflam-
matory Bowel Disease Questionnaire and EQ-5D-3L
questionnaires and found no significant difference in
global QoL when comparing IPAA and ileostomy,
despite ileostomy patients reporting decreased social
and sexual functioning. Notably, no studies commented
on the need for medication after surgery or return to
work following surgery.
Two studies compared IPAA to continued medical
therapy and were contradictory in their conclusion,
despite both using the SF-36 for global QoL assess-
ment. Meijs et al. [42] describe no significant difference
in global QoL between the cohorts, whereas van Gen-
nep et al. [53] describe a significantly improved global
QoL when undergoing IPAA. Both studies also used
the Colorectal Functional Outcome Questionnaire
which yielded similar results, reporting IPAA to signifi-
cantly increase stool frequency and the need for anti-di-
arrhoeal medication.
Ileal pouch–anal anastomosis outcomes
A full list of early and late outcomes for IPAA is pro-
vided in Table 3. A total of 35 early surgical complica-
tions were reported following IPAA reconstructive
surgery across 21 studies, but only seven studies defined
short-term complications as within 30 days of surgery.
Eleven studies reported eight late postoperative out-
comes with only four studies specifying the length of
follow-up, although this was variable between studies.
Eight of the early surgical complications were
reported in five or more studies and underwent formal
meta-analysis. A summary of the incidence and 95%
confidence intervals is provided in Fig. 2; forest plots
for each meta-analysis are provided in Figs S1–S8. The
incidence of small bowel obstruction (11.3%, 95% CI
6.6%–17.1%, I2 93%) was reported in 11 studies, whilst
wound infection (13.4%, 95% CI 9.5%–17.8%, I2 91%)
was reported in 10 studies. Ileus (11.7%, 95% CI 6.3%–
18.4%, I2 89%) and anastomotic leak (6.1%, 95% CI
2.5%–11.1%, I2 88%) were both reported in eight stud-
ies. Deep vein thrombosis (4.7%, 95% CI 3.3%–6.3%, I2
66%) was reported in six studies. Urinary tract infec-
tions (4.1%, 95% CI 0.94%–7.1%, I2 94%), pneumonia
(2.3%, 95% CI 0.94%–4.2%, I2 75%) and intraabdominal
collection (5.3%, 95% CI 2.1%–9.6%, I2 68%) were all
reported in five studies. Doi plots (Figs S9–S16) and
LFK indices indicated high levels of heterogeneity with
six of the eight complications showing major asymmetry
within the Doi plots.
IPAA pouch complications and functional outcomes
Sixteen studies reported 20 long-term pouch complica-
tions and functional outcomes (Table 4) with five
reporting follow-up time, four as a minimum of 1 year
and the other as 3–6 months. Pouch outcomes were
reported variably, e.g. most studies calculated mean
stool frequency; however, others opted to categorize
stool frequency as 1–6 or > 6.
Five of the pouch outcomes were reported in five
or more studies and underwent formal meta-analysis.
A summary of the incidence and 95% confidence inter-
vals is provided in Fig. 3; forest plots for each meta-
analysis are provided in Figs S17–S21. Chronic pouchi-
tis (23.0%, 95% CI 16.5%–30.2%, I2 91%) was the
most frequently reported pouch outcome (n = 14).
Anal stricture was reported in eight studies (10.8%,
95% CI 6.7%–15.6%, I2 85%), pouch failure (5.5%,
95% CI 1.9%–10.6%, I2 85%) in seven studies and
both pouch fistula (6.6%, 95% CI 3.2%–11%, I2 72%)
and faecal incontinence (18.6%, 95% CI 5.8%–35.8%,
I2 95%) were reported in five studies. Doi plots
(Figs S22–S26) and LFK indices suggested publication
bias in three of the outcomes, moderate bias in one
and no bias in one.
Subtotal colectomy with ileostomy outcomes
A total of 18 early surgical complications were reported
in three studies [35,46,51] (Table 5). One study [39]
reported three late complications of an end ileostomy
with a sample size of 24 patients. The complications
reported were peristomal skin irritation (13%), paras-
tomal hernia (39.1%) and stoma leak (17.4%).
Outcome definitions
Of the 35 studies in this review, five did not provide
outcome definitions as either (i) they reported mortality
only or (ii) they reported QoL only. Of the remaining
studies, 18 of the 30 did not report any definition of
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Table 3 Early and late IPAA complications.
Outcome
Number of studies
reporting outcome Reported incidence* (%) Reference of studies reporting outcome
Early complications
Small bowel obstruction 11 11.3 (6.6–17.1) 31, 32, 37, 38, 40, 41, 43, 45, 53, 54, 56
Intestinal perforation 1 4.8 31
DVT 6 4.7 (3.3–6.3) 29, 31, 34, 41, 47, 56
Wound infection 10 13.4 (9.5–17.8) 27, 38, 41, 45, 47, 49, 50, 54, 55, 56
Anastomotic leak 8 6.1 (2.5–11.1) 31, 34, 38, 40, 43, 53, 54, 56
UTI 5 4.1 (0.94–9.1) 37, 41, 45, 50, 56
Ileus 8 11.7 (6.3–18.4) 29, 31, 34, 41, 45, 47, 50, 55
Haemorrhage (postoperative) 2 3.2–8.3 40, 47
Pelvic abscess 3 1.7–17.8 30, 53, 56
30-day readmission 2 28.3–30.2 34, 40
Cardiac arrest 1 0.12 27
Pneumonia 5 2.3 (0.94–4.2) 27, 47, 50, 55, 56
Wound dehiscence 1 1.04 27
Sepsis 3 1.3–7.9 27, 43, 55
PE 1 1.04 27
30-day mortality 2 0.24–0.55 27, 31
30-day reoperation 2 6.5–7.5 27, 55
Intraabdominal collection 5 5.3 (2.1–9.6) 29, 40, 45, 50, 55
Tubo-ovarian abscess 1 2.1 29
Acute pouchitis 3 0.44–17 29, 41, 53
Pelvic sepsis 4 8.9–18.9 33, 34, 36, 41
Major complication
(Clavien–Dindo > 4)
1 17.9 38
Anal stricture dilation 1 22.3 31
Pouch leak 2 6.6–11.1 37, 45
Portal vein thrombosis 1 11.9 45
Any pulmonary complication 1 3.4 45
Perianal abscess 1 0.8 40
Pouch fistula 1 1.2 40
Abdominal wall haematoma 1 0.8 40
Anastomotic stenosis 1 2.8 40
Parastomal hernia 1 0.4 40
Pneumothorax 1 0.4 40
Any infectious complication 1 13.7 37
Length of stay 3 4–72 days 32, 45, 55
Operative time 1 359–560 min 32
Late complications
Impotence 3 4.2–40.5 22, 25, 33
Small bowel obstruction 4 1.7–19.5 23, 34, 38, 53
Pelvic abscess 1 8.1 23
Sexual dysfunction 2 11.3–33.1 23, 41
Infertility 1 37 52
Incisional hernia 3 2.7–5.2 34, 47, 54
Perianal abscess 1 7 38
Ileus 1 13.8 47
DVT, deep vein thrombosis; IPAA, ileal pouch–anal anastomosis; PE, pulmonary embolism; UTI, urinary tract infection.
*Reported as pooled incidence with 95% confidence interval for outcomes reported in five or more studies. For outcomes reported
in less than five studies they are reported as a range.
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the outcome measures used in their study. In the
remaining 12 studies, 14 of the 84 outcomes received
formal definitions (Table S3). Chronic pouchitis (n = 5,
three variations of definition) was the most frequently
defined, followed by pouch failure (n = 3, no varia-
tions) and small bowel obstruction (n = 2, two varia-
tions). The remaining outcomes were only defined once
so could not yield variable definitions.
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Figure 2 Summary of meta-analysis of early complications following ileal pouch–anal anastomosis.
Table 4 IPAA pouch complications and functional outcomes.
Outcome
Number of studies
reporting outcome
Reported
incidence* (%) Reference of studies reporting outcome
IPAA complications
De novo Crohn’s of the pouch 1 25 44
Chronic pouchitis 14 23.0 (16.5–30.2) 22, 23, 30, 33, 34, 38, 39, 41, 43, 44, 47, 49, 53, 54
Pouch failure 7 5.5 (1.9–10.6) 33, 34, 43, 44, 47, 54, 56
Pouch fistula 5 6.6 (3.2–11.0) 33, 34, 47, 54, 56
Faecal incontinence 5 18.6 (5.8–35.8) 22, 30, 39, 41, 54
Night defaecation 1 14 22
Anal pain 1 11.4 22
Pouch leakage 2 8.1–10.1 22, 49
Frequency 1 10.1 22
Anal stricture 8 10.8 (6.7–15.6) 23, 31, 33, 34, 49, 53, 54, 56
Pouch excision 1 3.4 23
Stool frequency 1–6 1 57.3 23
Stool frequency > 6 1 42.8 23
Night stools 1–2 1 75.2 23
Night stools > 2 1 23.4 23
Stool frequency (mean) 4 6–6.8 stool/day 30, 31, 39, 41
Stool frequency by
night (mean)
3 1.9–2 stools/night 30, 39, 41
Use of anti-diarrhoeals 2 36.6–57.5 30, 33
‘Very well’ functioning pouch 1 44.9 43
‘Adequate’ functioning pouch 1 49 43
IPAA, ileal pouch–anal anastomosis.
*Reported as pooled incidence with 95% confidence interval for outcomes reported in five or more studies. For outcomes reported
in less than five studies they are reported as a range.
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Sensitivity analysis
A sensitivity analysis was performed on studies with a
cohort of patients which was greater than 100 to com-
pare results of the meta-analysis with only larger cohort
studies (Table S4). Compared to overall rates, generally
there was not a large difference in pooled incidence
when using large cohorts only. Urinary tract infections
(4.1% vs 2.6%), ileus (11.7% vs 8.9%) and pouch failure
(5.5% vs 2.5%) had the largest reduction in incidence,
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Figure 3 Summary of meta-analysis of pouch long term and functional outcomes.
Table 5 Subtotal colectomy with ileostomy outcomes.
Outcome
Number of studies
reporting outcome Reported incidence* (%)
Reference of studies
reporting outcome
Early complications
Small bowel obstruction 2 2.2–9.1 35, 51
Deep vein thrombosis 2 2.2–2.4 35, 46
Wound infection 3 6.8–14 35, 46, 51
Urinary retention 1 6.8 35
Urinary tract infection 2 4.4–4.5 35, 46
Ileus 2 2.2–12 35, 51
Pelvic abscess 1 2.2 35
30-day readmission 2 12–13.6 35, 51
Cardiac arrest 1 0.19 46
Pneumonia 1 1.8 46
Wound dehiscence 1 3.3 51
Sepsis 1 7.9 46
Pulmonary embolism 1 0.79 46
30-day mortality 1 0.67 46
30-day reoperative rate 1 7.4 46
Major complications (Clavien–Dindo > 3) 1 9.9 35
Acute renal failure 1 0.33 46
Length of stay 2 3–72 days 35, 46
*Reported as range of incidence reported across studies.
ª 2020 The Authors. Colorectal Disease published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland 11
D. M. Baker et al. Outcomes after surgery for ulcerative colitis
whereas intraabdominal collection (5.3% vs 6.7%) and
chronic pouchitis (23% vs 23.6%) had a minor rise in
incidence for larger cohorts. Heterogeneity using the I2
statistic increased for all meta-analysis outcomes when
using larger cohort studies only.
Quality (risk of bias) assessment
Risk of bias was variable across the studies included
within our final analysis (Table S5); however, one of
the included studies used qualitative methodology and
thus could not be formally assessed. Generally, included
studies recruited participants appropriately and per-
formed appropriate statistical analyses. Twenty-four of
the included studies did not have an adequate sample
size and 23 did not use objective criteria for the mea-
surement of their outcomes. Studies were poor at com-
menting on the coverage of data within their sample –
in particular reporting how they dealt with missing or
incomplete data and the impact on reported incidence
rates. Lastly, only nine of the studies assessed provided
clear information on the effect of confounding factors
on the data reported.
Discussion
This systematic review and meta-analysis reports out-
comes after elective surgery for UC. Importantly, in
order to be able to counsel those considering elective
surgery for UC, and in contrast to previous reviews,
only patients undergoing elective surgery have been
included. In addition, the cohorts were restricted to
patients who underwent surgery during or after 2002.
This method has been adopted previously in the litera-
ture as this is when routine biologic agents became uni-
versally available in clinical practice [11]. In this review,
34 studies were identified with a total of 11 774
patients enrolled across the studies.
QoL was reported using a variety of different tools
and was measured both in isolated IPAA operative
cohorts and in comparator studies to ileostomy patients
or medical therapy patients. Generally, QoL was reported
to be increased for patients undergoing IPAA, despite a
significant number of patients experiencing pouch-related
symptoms [25]. Studies comparing continued medical
therapy to elective surgery contrasted in that QoL was
reported to be superior in elective surgery in one study
[53] but comparable in another [42], despite utilization
of the same QoL questionnaire. This is probably due to
heterogeneity in the study population but may also repre-
sent differential analysis utilized within each study. The
variability observed in studies reporting QoL further reit-
erates the equipoise in this decision, and that the decision
should be based on patient preferences.
Identified studies reporting outcomes following elec-
tive surgery for UC predominantly focus on IPAA – the
most common reconstructive operation in the time per-
iod studied. In our review, only 14 of the 84 outcomes
reported received a formal definition within the original
study, and importantly definitions of the same outcome
were often variable between studies. This is further illus-
trated in our risk of bias assessment where only 10 stud-
ies used objective, standard criteria for measurement of
a condition, although the majority of these studies used
validated QoL questionnaires. Recent systematic reviews
in colorectal surgery have highlighted the range of defi-
nitions used within studies for the same outcome
[57,58]. The results of our review highlight not only
the need for a core outcome set when reporting elective
surgery for UC but also the need to provide formal def-
initions of outcome measures a priori.
There are some limitations to our study. There was
a high degree of heterogeneity within our meta-analy-
sis. It is likely that the heterogeneity within our study
is due to the lack of definition of outcome measures,
variability in definitions of those that were defined and
also variation in the length of follow-up time between
studies. Intervention factors may also contribute to the
observed heterogeneity, particularly the number of
stages over which an IPAA was carried out. Whilst the
Cochrane Handbook does not advocate meta-analysis in
settings of high heterogeneity, we have made a con-
scious decision to perform this here for two reasons.
First, without the pooling of data there is a wide
range of incidences that could be quoted to patients
which could lead to overestimation or underestimation
of outcomes, which may directly influence patient deci-
sion making. Second, quantifying the levels of uncer-
tainty around an event – or in this case high levels of
heterogeneity – is noted to be an essential component
to shared decision making in clinical practice [59]. By
providing clinicians with a single incidence rate of
common outcomes, with the levels of uncertainty
around these outcomes, we provide the materials to
clinicians to facilitate shared decision making in clinical
practice in the context of elective surgery for UC. We
recognize that we did not search the Cochrane Library
for pragmatic reasons and it may yield additional stud-
ies; however, our combination of MEDLINE and
Embase has been proved not to affect the significance
of results of meta-analyses in the vast majority of
cases [60].
We did not perform a subgroup analysis as post hoc
visualization of the included patient demographics
demonstrated a gross variation in reporting of demo-
graphics that made identification of subgroups not pos-
sible. The most pertinent subgroup which we could not
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identify is those on preoperative biologics: however,
there are several publications within the literature that
note either no or a very small increased impact of the
use of biologics on postoperative outcomes in UC
patients [61,62].
Outcomes were split by early and late complications
as defined by the individual study, although many stud-
ies did not provide formal definitions of these time peri-
ods. We still opted to compile the results in this way as
this method has been previously adopted in the litera-
ture by Peyrin-Biroulet et al. [11]. In our review we
opted not to meta-analyse QoL data for a variety of rea-
sons: primarily a large number of different question-
naires were used, but also questionnaires were analysed
differently depending on the individual study methodol-
ogy; thus formal synthesis was not possible or compara-
ble. It is therefore recommended that when counselling
patients on QoL after surgery, clinicians summarize the
general QoL findings reported in this study but also the
uncertainty in QoL post-surgery – noting that the litera-
ture around QoL is contrasting. Finally, we restricted
the sample size of included studies to 20 or more
patients. Small sample sizes may introduce bias into the
observed incidence in a particular study; however, as we
aimed to review all outcomes as well as QoL, it was nec-
essary to maintain a low threshold for inclusion. A sensi-
tivity analysis was performed to examine the effect of
sample size on observed incidence. The exclusion of
smaller studies (< 100 participants) led to minor alter-
ations in observed incidence in all outcomes that were
meta-analysed. Heterogeneity increased in all outcomes
following the removal of smaller studies which further
supports the need for inclusion of smaller studies in our
meta-analysis.
In summary, both short- and long-term complica-
tions following surgery for UC are common and vari-
ably reported. QoL studies produce variable results and
it is clear that there are contrasting results in QoL
before and after elective surgery for UC, as well as
between the different reconstructive surgical options. It
is therefore essential that clinicians adopt a shared deci-
sion making model in clinical practice to allow patients
to consider the risks and benefits of all options to ulti-
mately make a decision based on their preferences. The
results of this systematic review and meta-analysis pro-
vide an up-to-date quantification of the clinical out-
comes following elective surgery for UC, and the
different reconstructive surgical operations, in the era of
routine biologic use. It is anticipated that the results of
this study will guide clinicians in their reporting of risks
to patients, as well as provide information on the levels
of uncertainty around such events. The significant limi-
tations of this meta-analysis can only be resolved if
future studies include (i) a core outcome set for studies
reporting elective surgery for UC (including a standard-
ized measure of QoL) and (ii) high-quality prospective
data collection.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Forest plot for small bowel obstruction.
Figure S2. Forest plot for wound infection.
Figure S3. Forest plot for ileus.
Figure S4. Forest plot for anastomotic leak.
Figure S5. Forest plot for deep vein thrombosis.
Figure S6. Forest plot for urinary tract infection.
Figure S7. Forest plot for pneumonia.
Figure S8. Forest plot for intraabdominal collection.
Figure S9. Small bowel obstruction Doi plot.
Figure S10. Wound infection Doi plot.
Figure S11. Ileus Doi plot.
Figure S12. Anastomotic leak Doi plot.
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Figure S13. Deep vein thrombosis Doi plot.
Figure S14. Urinary tract infection Doi plot.
Figure S15. Pneumonia Doi plot.
Figure S16. Intraabdominal collection Doi plot.
Figure S17. Forest plot for chronic pouchitis.
Figure S18. Forest plot for anal stricture.
Figure S19. Forest plot for pouch failure.
Figure S20. Forest plot for pouch fistula.
Figure S21. Forest plot for faecal incontinence.
Figure S22. Doi plot for chronic pouchitis.
Figure S23. Doi plot for anal stricture.
Figure S24. Doi plot for pouch failure.
Figure S25. Doi plot for pouch fistula.
Figure S26. Doi plot for faecal incontinence.
Table S1. Search strategy.
Table S2. Studies assessing QoL and the methods used
for QoL assessment.
Table S3. Summary of outcomes reported by study, as
well as definition of outcomes used in each study.
Table S4. Sensitivity analysis results.
Table S5. Risk of bias assessment using the Munn
et al. tool [22].
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